<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33528827</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-2443</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of neurovirology</Title><ISOAbbreviation>J Neurovirol</ISOAbbreviation></Journal><ArticleTitle>Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19.</ArticleTitle><Pagination><StartPage>154</StartPage><EndPage>159</EndPage><MedlinePgn>154-159</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13365-021-00949-1</ELocationID><Abstract><AbstractText>As the SARS-COV-2 becomes a global pandemic, many researchers have a concern about the long COVID-19 complications. Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a persistent, debilitating, and unexplained fatigue disorder. We investigated psychological morbidities such as CFS and post-traumatic stress disorder (PTSD) among survivors of COVID-19 over 6 months. All COVID-19 survivors from the university-affiliated hospital of Tehran, Iran, were assessed 6 months after infection onset by a previously validated questionnaire based on the Fukuda guidelines for CFS/EM and DSM-5 Checklist for PTSD (The Post-traumatic Stress Disorder Checklist for DSM-5 or PCL-5) to determine the presence of stress disorder and chronic fatigue problems. A total of 120 patients were enrolled. The prevalence rate of fatigue symptoms was 17.5%. Twelve (10%) screened positive for chronic idiopathic fatigue (CIF), 6 (5%) for CFS-like with insufficient fatigue syndrome (CFSWIFS), and 3 (2.5%) for CFS. The mean total scores in PCL-5 were 9.27&#x2009;&#xb1;&#x2009;10.76 (range:0-44), and the prevalence rate of PTSD was 5.8%. There was no significant association after adjusting between CFS and PTSD, gender, comorbidities, and chloroquine phosphate administration. The obtained data revealed the prevalence of CFS among patients with COVID-19, which is almost similar to CFS prevalence in the general population. Moreover, PTSD in patients with COVID-19 is not associated with the increased risk of CFS. Our study suggested that medical institutions should pay attention to the psychological consequences of the COVID-19 outbreak.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simani</LastName><ForeName>Leila</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramezani</LastName><ForeName>Mahtab</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1148-3998</Identifier><AffiliationInfo><Affiliation>Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. drramezani23@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darazam</LastName><ForeName>Ilad Alavi</ForeName><Initials>IA</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Tropical Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagharichi</LastName><ForeName>Mastooreh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aalipour</LastName><ForeName>Mohammad Amin</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghorbani</LastName><ForeName>Fatemeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pakdaman</LastName><ForeName>Hossein</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Brain Mapping Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurovirol</MedlineTA><NlmUniqueID>9508123</NlmUniqueID><ISSNLinking>1355-0284</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003371" MajorTopicYN="N">Cough</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004417" MajorTopicYN="N">Dyspnea</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015673" MajorTopicYN="N">Fatigue Syndrome, Chronic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005334" MajorTopicYN="N">Fever</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013313" MajorTopicYN="N">Stress Disorders, Post-Traumatic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017741" MajorTopicYN="N">Survivors</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Chronic fatigue syndrome / myalgic encephalomyelitis</Keyword><Keyword MajorTopicYN="N">Post-COVID morbidities</Keyword><Keyword MajorTopicYN="N">Post-traumatic stress disorder</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest. </CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>2</Day><Hour>12</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33528827</ArticleId><ArticleId IdType="pmc">PMC7852482</ArticleId><ArticleId IdType="doi">10.1007/s13365-021-00949-1</ArticleId><ArticleId IdType="pii">10.1007/s13365-021-00949-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baraniuk JN (2017) Chronic fatigue syndrome prevalence is grossly overestimated using Oxford criteria compared to Centers for Disease Control (Fukuda) criteria in a U.S. population study. Fatigue: Biomedicine, Health &amp; Behavior 5(4):215&#x2013;230</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6407870</ArticleId><ArticleId IdType="pubmed">30854252</ArticleId></ArticleIdList></Reference><Reference><Citation>Baraniuk JN, Adewuyi O, Merck SJ, Ali M, Ravindran MK, Timbol CR, Rayhan R, Zheng Y, Le U, Esteitie R. A chronic fatigue syndrome (CFS) severity score based on case designation criteria. Am J Transl Res. 2013;5(1):53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560481</ArticleId><ArticleId IdType="pubmed">23390566</ArticleId></ArticleIdList></Reference><Reference><Citation>Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The posttraumatic stress disorder checklist for DSM-5 (PCL-5): development and initial psychometric evaluation. J Trauma Stress. 2015;28(6):489&#x2013;498. doi: 10.1002/jts.22059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jts.22059</ArticleId><ArticleId IdType="pubmed">26606250</ArticleId></ArticleIdList></Reference><Reference><Citation>Bovin MJ, Marx BP, Weathers FW, Gallagher MW, Rodriguez P, Schnurr PP, Keane TM. Psychometric properties of the PTSD checklist for diagnostic and statistical manual of mental disorders&#x2013;fifth edition (PCL-5) in veterans. Psychol Assess. 2016;28(11):1379. doi: 10.1037/pas0000254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/pas0000254</ArticleId><ArticleId IdType="pubmed">26653052</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, Staines D, Powles AP, Speight N, Vallings R. Myalgic encephalomyelitis: international consensus criteria. J Intern Med. 2011;270(4):327&#x2013;338. doi: 10.1111/j.1365-2796.2011.02428.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2011.02428.x</ArticleId><ArticleId IdType="pmc">PMC3427890</ArticleId><ArticleId IdType="pubmed">21777306</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med. 1994;121(12):953&#x2013;959. doi: 10.7326/0003-4819-121-12-199412150-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-121-12-199412150-00009</ArticleId><ArticleId IdType="pubmed">7978722</ArticleId></ArticleIdList></Reference><Reference><Citation>Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nat Rev Immunol. 2005;5(3):243&#x2013;251. doi: 10.1038/nri1571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1571</ArticleId><ArticleId IdType="pubmed">15738954</ArticleId></ArticleIdList></Reference><Reference><Citation>Hives L, Bradley A, Richards J, Sutton C, Selfe J, Basu B, Maguire K, Sumner G, Gaber T, Mukherjee A. Can physical assessment techniques aid diagnosis in people with chronic fatigue syndrome/myalgic encephalomyelitis? A diagnostic accuracy study. BMJ Open. 2017;7(11):e017521. doi: 10.1136/bmjopen-2017-017521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2017-017521</ArticleId><ArticleId IdType="pmc">PMC5695376</ArticleId><ArticleId IdType="pubmed">29133321</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam MF, Cotler&#xa0;J,&#xa0;Jason&#xa0;LA&#xa0;(2020) Post-viral fatigue and COVID-19: lessons from past epidemics. Fatigue: Biomedicine, Health &amp; Behavior 1&#x2013;9</Citation></Reference><Reference><Citation>Jiang T, Farkas DK, Ahern TP, Lash TL, S&#xf8;rensen HT, Gradus JL. Posttraumatic stress disorder and incident infections: a nationwide cohort study. Epidemiology. 2019;30(6):911&#x2013;917. doi: 10.1097/EDE.0000000000001071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0000000000001071</ArticleId><ArticleId IdType="pmc">PMC6779341</ArticleId><ArticleId IdType="pubmed">31584893</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam MH-B, Wing Y-K, Yu MW-M, Leung C-M, Ma RC, Kong AP, So W, Fong SY-Y, Lam S-P. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch Intern Med. 2009;169(22):2142&#x2013;2147. doi: 10.1001/archinternmed.2009.384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinternmed.2009.384</ArticleId><ArticleId IdType="pubmed">20008700</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim EJ, Ahn YC, Jang ES, Lee SW, Lee S-H, Son CG. Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) J Transl Med. 2020;18(1):1&#x2013;15. doi: 10.1186/s12967-019-02189-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-019-02189-8</ArticleId><ArticleId IdType="pmc">PMC7038594</ArticleId><ArticleId IdType="pubmed">32093722</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnus P, Gunnes N, Tveito K, Bakken IJ, Ghaderi S, Stoltenberg C, Hornig M, Lipkin WI, Trogstad L, H&#xe5;berg SE. Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is associated with pandemic influenza infection, but not with an adjuvanted pandemic influenza vaccine. Vaccine. 2015;33(46):6173&#x2013;6177. doi: 10.1016/j.vaccine.2015.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.10.018</ArticleId><ArticleId IdType="pubmed">26475444</ArticleId></ArticleIdList></Reference><Reference><Citation>Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol. 2011;11(1):37. doi: 10.1186/1471-2377-11-37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-11-37</ArticleId><ArticleId IdType="pmc">PMC3071317</ArticleId><ArticleId IdType="pubmed">21435231</ArticleId></ArticleIdList></Reference><Reference><Citation>Organization WH (1992) The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Weekly Epidemiological Record= Relev&#xe9; &#xe9;pid&#xe9;miologique hebdomadaire 67(30):227</Citation></Reference><Reference><Citation>Passos IC, Vasconcelos-Moreno MP, Costa LG, Kunz M, Brietzke E, Quevedo J, Salum G, Magalh&#xe3;es PV, Kapczinski F, Kauer-Sant'Anna M. Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. The Lancet Psychiatry. 2015;2(11):1002&#x2013;1012. doi: 10.1016/S2215-0366(15)00309-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(15)00309-0</ArticleId><ArticleId IdType="pubmed">26544749</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin R, Riste L, Hann M, Walther A, Mukherjee A, Heald A. Into the looking glass: post-viral syndrome post COVID-19. Med Hypotheses. 2020;144:110055. doi: 10.1016/j.mehy.2020.110055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110055</ArticleId><ArticleId IdType="pmc">PMC7320866</ArticleId><ArticleId IdType="pubmed">32758891</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramezani M, Simani L, Karimialavijeh E, Rezaei O, Hajiesmaeili M, Pakdaman H. The role of anxiety and cortisol in outcomes of patients with Covid-19. Basic and Clinical Neuroscience. 2020;11(2):179. doi: 10.32598/bcn.11.covid19.1168.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.32598/bcn.11.covid19.1168.2</ArticleId><ArticleId IdType="pmc">PMC7368100</ArticleId><ArticleId IdType="pubmed">32855777</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghi M, Taghva A, Goudarzi N, Rah Nejat A. Validity and reliability of persian version of &#x201c;post-traumatic stress disorder scale&#x201d; in war veterans. Iranian Journal of War and Public Health. 2016;8(4):243&#x2013;249.</Citation></Reference><Reference><Citation>Shephard RJ. Chronic fatigue syndrome. Sports Med. 2001;31(3):167&#x2013;194. doi: 10.2165/00007256-200131030-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00007256-200131030-00003</ArticleId><ArticleId IdType="pubmed">11286355</ArticleId></ArticleIdList></Reference><Reference><Citation>Speer K, Upton D, Semple S, McKune A. Systemic low-grade inflammation in post-traumatic stress disorder: a systematic review. J Inflamm Res. 2018;11:111. doi: 10.2147/JIR.S155903.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S155903</ArticleId><ArticleId IdType="pmc">PMC5868606</ArticleId><ArticleId IdType="pubmed">29606885</ArticleId></ArticleIdList></Reference><Reference><Citation>Tansey CM, Louie M, Loeb M, Gold WL, Muller MP, de Jager J, Cameron JI, Tomlinson G, Mazzulli T, Walmsley SL. One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome. Arch Intern Med. 2007;167(12):1312&#x2013;1320. doi: 10.1001/archinte.167.12.1312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.167.12.1312</ArticleId><ArticleId IdType="pubmed">17592106</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyas KJ, Delaney EM, Webb-Murphy JA, Johnston SL. Psychological impact of deploying in support of the US response to Ebola: a systematic review and meta-analysis of past outbreaks. Mil Med. 2016;181(11&#x2013;12):e1515&#x2013;e1531. doi: 10.7205/MILMED-D-15-00473.</Citation><ArticleIdList><ArticleId IdType="doi">10.7205/MILMED-D-15-00473</ArticleId><ArticleId IdType="pubmed">27849485</ArticleId></ArticleIdList></Reference><Reference><Citation>Weathers FW, Litz&#xa0;BT,&#xa0;Keane TM, Palmieri PA, Marx&#xa0;BP, Schnurr PP (2013) The ptsd checklist for dsm-5 (pcl-5).&#xa0;Scale available from the National Center for PTSD at https://www.ptsd.va.gov10</Citation></Reference><Reference><Citation>Wu KK, Chan SK, Ma TM. Posttraumatic stress after SARS. Emerg Infect Dis. 2005;11(8):1297. doi: 10.3201/eid1108.041083.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1108.041083</ArticleId><ArticleId IdType="pmc">PMC3320475</ArticleId><ArticleId IdType="pubmed">16102324</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>